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ABSTRACT 
 
Development of High-throughput and Robust Microfluidic Live Cell Assay Platforms 
for Combination Drug and Toxin Screening. (December 2011) 
Han Wang, B.E., Tsinghua University, China 
Chair of Advisory Committee: Dr. Arum Han 
 
 In both combination chemotherapy and environmental toxicology studies, 
characterizing effects of mixtures of drugs or toxins rather than simply analyzing the 
effects of single drugs or toxins are of significant interest.  In order to determine such 
combination effects, it is necessary to systematically investigate interactions between 
different concentration-dependent components of a mixture.  Conventional microtiter 
plate format based assays are efficient and cost-effective, however are not practical as 
the number of combinations increases drastically.  Microfluidic live cell screening 
platforms can allow precise control of cell culture microenvironments by applying 
accurate doses of biomolecular mixtures with specific mixing ratios generated through 
integrated on-chip microfluidic gradient generators. 
This thesis first presents a live cell array platform with integrated microfluidic 
network-based gradient generator which enables generation and dosing of 64 unique 
combinations of two cancer drugs at different concentrations to an 8 by 8 cell culture 
chamber array.  We have developed the system into a fully automated microfluidic live 
cell screening platform with uniform cell seeding capability and pair-wise gradient 
 iv 
profile generation.  This platform was utilized to investigate the gene expression 
regulation of colorectal cancer cells in response to combination cancer drug treatment.  
The resulting cell responses indicate that the two cancer drugs show additive effect when 
sequential drug treatment scheme is applied, demonstrating the utility of the microfluidic 
live cell assay platform. 
However, large reagent consumption and difficulties of repeatedly generating the 
exact same concentrations and mixture profiles from run to run due to the fact that the 
generated mixture profiles have to rely on stable flow at optimized flow rate throughout 
the entire multi-day experiment limit the widespread use of this method.  Moreover, 
producing three or more reagent mixtures requires complicated microchannel structures 
and operating procedures when using traditional microfluidic network-based gradient 
generators.  Therefore, an on-demand geometric metering-based mixture generator 
which facilitates robust, scalable, and accurate multi-reagent mixing in a high-
throughput fashion has been developed and incorporated with a live cell array as a 
microfluidic screening platform for conducting combination drug or toxin assays.  
Integrated single cell trapping array allowed single cell resolution analysis of drugs and 
toxin effects.  Reagent mixture generation and precise application of the mixtures to 
arrays of cell culture chambers repeatedly over time were successfully demonstrated, 
showing significantly improved repeatability and accuracy than those from conventional 
microfluidic network-based gradient generators.  The influence of this improved 
repeatability and accuracy in generating concentration specified mixtures on obtaining 
more reliable and repeatable biological data sets were studied. 
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CHAPTER I 
INTRODUCTION 
 
1.1.      Combination Chemotherapy 
 Cancer cells are multigenic and can develop heterogeneity through the process of 
cell cycling, as well as the adaptive resistance to drugs that are targeting an individual 
molecule, leading to the loss of efficacy of conventional monotherapies.  In some cases, 
the effectiveness of these monotherapies is further reduced due to the buffering effects of 
complex biological systems.  In a complex disease system like cancer, multiple cellular 
activity pathways have been modified, thus it is natural to develop a strategy which 
attacks cancer in multiple aspects concurrently [1].  Therefore, researchers have adopted 
combination chemotherapy strategies where multiple agents with different mechanisms 
of actions are applied [2].  This kind of multi-target therapeutics can be more efficacious 
and less vulnerable to adaptive resistance. 
            Early development of combination chemotherapy was based on a simple 
assumption that the maximum therapeutic effect can be achieved by implementing each 
drug at its maximum tolerated dose (MTD).  However, it has been revealed that the 
therapeutic effect of combination chemotherapy would largely depend on the dosage 
ratios of each drug in a combination, instead of their absolute doses [3].  This can be 
explained by the drug-receptor interaction theory, which is the basic principle 
underlining drug treatment.  Drug induced effects are generally mediated by  
____________ 
This thesis follows the style of Lab on a Chip. 
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corresponding receptors, which can be described by the equation [RD] = [RT] × [D] / 
(KD + [D]), where [RD] is the concentration of receptor-drug complex, [RT] is the total 
receptor concentration, [D] is the concentration of free drug (not bound to receptor), and 
KD is the equilibrium dissociation constant for the binding of free drug D to free receptor 
R to form the RD complex, defined by the reaction R + D ↔ RD.  Therefore, the dose 
and mixing ratios must be optimized to establish combination chemotherapy [4].   
            From the perspective of drug-receptor interaction theory, the drug combination 
can be classified as agonism (each drug binds and activates the receptor), antagonism 
(some drug only binds to the receptor but doesn‟t activate it), and inverse agonism (some 
drug binds and inactivates the receptor).  With regard to the quantitative nature of 
combination effects, the drug combinations can be classified as additivity (combination 
effect equals the sum effect of individual drugs), subadditivity (combination effect is less 
than the sum effect of individual drugs), and superadditivity (combination effect is larger 
than the sum effect of individual drugs).  A representative type of superadditivity, 
synergy, refers to the case in which each of the drugs exhibits its own effects and the 
effects of the combination are obviously greater.  Synergy occurs in situations where 
either or both drugs in a combination have amplifying effects on the other.    
 
1.2.      Microfluidic Live Cell Assay 
 Live cell assays based on plastic culture plates (including microtiter plates) have 
been developed as tools for the characterization of the relationships between cell states, 
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environmental stimuli, and cellular responses.  The three basic requirements of a live cell 
assay system are as follows [5]: 
            a)  to maintain the viability of cell culture in vitro (subject); 
            b)  to control the delivery and treatment of environmental stimuli (input); 
            c)  to measure cellular response (output). 
 Conventional live cell assays are typically performed in culture flasks, petri 
dishes, and microtiter plates.  These systems are extensively used due to cost efficiency, 
simplicity, standardized dimensions, automated equipments, and are gold standards for 
live-cell assay.  However, these methods suffer from large reagent consumption, low 
throughput, time-consuming procedures, and labor-intensive operations.  Automatic 
pipetting systems can overcome the limitations of low throughput, extended time length, 
and manual intervention, however are generally costly and not commonly available.  
Also, these conventional methods have difficulties in mimicking in vivo-like cell 
microenvironments in vitro[6]. 
            As an emerging technology, microfluidics enables precise and flexible control of 
cell microenvironments at the micro- and submicrometer scale.  Microfluidic systems 
allow manipulating extremely small amount of samples and reagents with high 
precision.  Laminar flow arises as the dominant flow transportation method in 
microfluidic devices due to low Reynolds number, which facilitates spatially controlled 
reagent delivery.  Furthermore, the small dimensions of microfluidic components such as 
microvalves, micropumps, microreactors, gradient generators, and multiplexers and the 
ability of high level integration of such functional components enable building a 
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complete live cell culture and assay platform on a single chip, so called “lab-on-a-chip”, 
or “micro total analysis systems” (µTAS).  Various microfluidic live cell assay systems 
have been developed in the past decade, including devices that allow  differential 
treatment of sub-cellular regions of a single bovine capillary endothelial cell by multiple 
laminar flow [7], long-term culture and monitoring of extremely small populations of 
bacteria with single cell resolution in a microchemostat array [8], continuous perfusion 
of humane carcinoma (HeLa) cells with repeated cell growth/passage cycles [9], and 
continuous separation of blood plasma utilizing the pinched flow fraction scheme [10].  
These examples show the capability and potential of microfluidic and lab-on-a-chip 
platform for cellular assays and studies. 
            Microfluidic devices have been fabricated in silicon, glass, and a wide range of 
polymers.  The development of soft lithography [11], a series of techniques where 
elastomeric devices can be replicated from a single master mold repeatedly, has 
proliferated the development and usage of microfluidic devices and systems to the 
broader life science community.  This method is cheap, more accessible to general 
researchers, capable of patterning non-planar and 3D structures, and compatible with a 
variety of polymers such as elastomers.  Poly(dimethylsiloxane) (PDMS) has been 
generally used for its transparency, gas permeability, biocompatibility, and surface 
properties.  The cast molding fabrication procedure goes as following: the master is 
prepared by photolithography, hot embossing, or other techniques; and then PDMS base 
and curing agent are mixed and poured onto the master; then the PDMS mixture is cured 
by heat, released from the master, and bonded to glass or other substrates by oxygen 
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plasma treatment.  Pieces of partially cured PDMS blocks can also be bonded by 
attaching them together and fully curing the system.   
              
1.3.      Microfluidic High-throughput Screening Systems 
 Over the past twenty years, technological advancements in automation and 
miniaturization as well as economic pressures have driven rapid development of high-
throughput screening (HTS) techniques.  HTS has been established as the main 
technique for toxicology research and drug discovery in pharmaceutical companies as 
well as in research laboratories.  Typical HTS systems can perform over 10,000 assays 
per day, while ultraHTS (uHTS) systems can perform over 100,000 assays per day.  The 
ever increasing need for HTS stems from the growing number of potential therapeutic 
molecular targets emerging from functional genomic studies as revealed by the human 
genome program, and the rapid development of large compound libraries derived from 
parallel and combinatorial chemical synthesis techniques [12].  Solution-based HTS is 
the primary step to identify the potential lead, which is capable of modulating target 
biochemical molecules from a large library of compounds.  Cell-based HTS aims to 
build integrated platforms that enable automated monitoring of molecular processes 
within cells (e.g. gene expression modulation) and cell functionality changes (e.g. 
apoptosis), as well as to facilitate target validation and lead optimization.  The earlier 
cell-based HTS assays are applied in the drug development cascade, the better quality of 
leads can be identified with reduced lead failures. 
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Miniaturization of HTS has scaled down the conventional petri dish into 96-well, 
384-well, and 1536-well microtiter plate formats, and automatic plate reader has been 
developed to quantitatively analyze the screening data in a high-throughput fashion.  
This microtiter based HTS technique benefits from standardized dimensions and 
compatibility with laboratory automation instruments, and has been accepted as the 
standard approach in chemistry and biology fields.  However, further miniaturization of 
microtiter plates turned out impractical due to expedited medium evaporation, increased 
surface-to-volume ratio, and increased surface tension.  Furthermore, this method is 
inefficient in delivering temporarily and spatially varying stimuli, controlling cell 
position and local density, thus giving rise to the need for next generation HTS 
techniques [5]. 
Microfluidic live cell assay platform holds the potential as next generation HTS 
technology for  its precise and flexible control capability of cell microenvironment, 
capability of dynamically controlled cell and fluid delivery dynamically over time, 
reduced reagent volume, capability of automation, multi-functionality, and scalability. 
Wang, et al., developed a 24×24 sieve embedded circular chamber microfluidic 
cytotoxicity array which could test six distinct cell lines with twelve toxins formulations 
[13].  Cell seeding channels were orthogonal to toxin injection channels, and within each 
channel intersection was a circular chamber with cell-trapping sieves.  This 576-chamber 
microfluidic array was used to screen three cell types (BALB/3T3, HeLa, and bovine 
endothelial cells) against a panel of five toxins (digitonin, saponin, CoCl2, NiCl2, 
acrolein) by fluorescence microscopy to demonstrate its functionality. 
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Lee, et al., developed an addressable 8×8 array of cell culture chambers with an 
integrated microfluidic gradient generator to observe the serum response of HeLa human 
cancer cells in 64 parallel cultures [14].  Each cell culture chamber was designed with a 
„„C‟‟ shaped ring to effectively decouple the central cell growth regions from the outer 
fluid transport channels.  This microfluidic device overcame major problems in 
multiplexing nanoliter culture environments by enabling uniform cell loading, 
eliminating shear and pressure stresses on cultured cells, providing stable control of 
fluidic addressing, and permitting continuous on-chip optical monitoring. 
 
1.4.      Microfluidic Single Cell Assay Platforms 
            In recent years, single cell level analysis has drawn significant interest in 
comparison to conventional population based cell group analysis [15].  Single cell assay 
not only pushes the resolution to an individual cell level, but also offers enormous 
potentials in studying cell heterogeneity and individual cell behaviors, such as cell 
growth, differentiation, and apoptosis.  Also single cell assay opens the window of 
studying sub-cellular activities and molecular processes more directly.  Moreover, the 
isolation of individual cells provides quantitative information on the heterogeneous 
behaviors of individual cells not obtainable through population-based studies. 
            Microfluidic systems are ideal methods for single cell assay due to their exquisite 
capability for manipulating small volume of samples down to single cells, and have been 
used for applications such as single cell microinjection where single cells were directed 
to a fixed microneedle [16], counting low-copy number proteins in a single cell by 
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manipulating, lysing, labeling, and quantifying the protein content of a single cell [17], 
and monitoring single cell secretion in real-time with confocal microscopy [18]. 
            Single cell trapping enables easy tracking/analysis of single cell level gene 
expression.  Various microfluidic single cells trapping schemes have been demonstrated, 
such as hydrodynamic trapping with physical obstacles, or trapping with applied external 
forces such as dielectrophoresis (DEP), magnetic field, and acoustic waves [19].  
Hydrodynamic trapping of individual cells with physical obstacles offers a simple, 
effective, and physiologically favorable solution for isolating single cells in a high-
throughput manner.  Di Carlo, et al. has developed a large scale single cell trapping 
array with raised trapping structures for studying dynamic cell growth and division on 
chip [20].  A derivative of this trapping scheme will be implemented into our developed 
high-throughput single cell environmental toxin screening platform integrated with 
geometric metering-based concentration mixture generator to allow quantitative single 
cell resolution toxin treatment analysis. 
 
1.5.      Organization of the Thesis 
 The thesis will describe the development of high-throughput and robust 
microfluidic live cell combination screening platforms, including the designs and 
working principles, fabrication, and experimental results. 
Chapter II will present a microfluidic network-based gradient generator device 
used for high-throughput screening of the combination gene regulations of HCT116 
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colorectal cancer cells with two cancer drugs.  A design of two pair-wised gradient 
generators with integrated cell culture array will be demonstrated. 
A novel geometric metering-based mixture generator and fluid delivery scheme 
for on-demand combination environmental toxin mixture generation and exposure on 
hepatoma cells will be demonstrated in Chapter III.  This innovative approach 
overcomes limitations of conventional networked-based gradient generator in multiple 
aspects and enables robust and scalable multi-reagent mixture generation by “hardware 
programming”.  The pressurized membrane pumping (PMP) method enables robust and 
accurate fluid delivery in the microfluidic cell culture system. 
Chapter IV will summarize the thesis and give the directions and plan for future 
research of the developed platform. 
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CHAPTER II 
MICROFLUIDIC NETWORK-BASED LIVE CELL COMBINATION  
DRUG SCREENING PLATFORM 
 
2.1.      Introduction 
Laminar flow phenomena in microfluidics allows the generation of fluidic 
gradients, which can then be used to generate mixtures of two reagents at various 
concentrations.  The most widely used microfluidic gradient generator is the network-
based gradient generator as in the configuration of series of serpentine channels which 
can generate spatially and temporally constant gradient profiles by repeatedly splitting, 
mixing and combining inlet fluids [21].  Since the first introduction by Jeon, et al., this 
kind of network-based gradient generator and its derivatives have won great popularity 
due to its simplicity of operation, capability of generating predictable, and complex 
gradient profiles, and adaptability to general settings [22, 23].  Figure 2.1 shows a simple 
microfluidic gradient generator demonstrating the generation of 8 different 
concentrations of color dye using series of splitting, mixing, and combining microfluidic 
channel network.  In this particular example, 8 different concentration combinations are 
generated automatically by simply pushing blue dye (inlet A) and red dye (inlet B) into 
the two inlets at equal speed.  This gradient profile can be adjusted by varying relative 
flow rates of the two inlet solutions, and more complex gradient profiles can be achieved 
by adding more inlets or apply complex control schemes.  Using this concept, linear, 
logarithmic, and arbitrary concentrations of chemicals have been generated by various 
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researchers.  More complex profiles can also be achieved by introducing multiple inlets 
[23].  Concentration gradient profiles can be calculated through an analogy with an 
equivalent electrical circuit model [22].   
Our microfluidic live cell assay platform utilizes the basic gradient generation 
scheme shown in Figure 2.1, and spatially and temporally constant gradients can be 
generated at stable flow rates of inlet solutions.   
 
2.2.      Design and Fabrication 
            This design used here is adopted from the microfluidic platform initially 
developed by our collaborator Kim et al. [24].  The high-throughput combination drug 
screening platform consists of two orthogonally positioned microfluidic network-based 
gradient generators and an array of 64 cell culture chambers (chamber size: 700 µm × 
700 µm) with four symmetric cell-seeding ports (Figures 2.2 & 2.3).  Two gradient 
microvalves control the opening/closure of both gradient generators, respectively.  The 
two chamber microvalves control the cell culture chamber array in two orthogonal 
directions.  By actuating the gradient microvalve with chamber microvalve in the same 
direction, cells trapped inside the culture chambers can be exposed to the chemical 
gradient from one gradient generator while isolated from the chemical gradient of the 
other gradient generator.  The drug exposure profile after exposing the cell culture  
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Inlet A
Inlet B
Outlet
 
Figure 2.1.  A microfluidic network-based gradient generator.   
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chambers with gradient of drug B was simulated by color dyes as shown in Figure 
2.3(A).  Together with the second gradient generator for drug A, this configuration 
allows the 64 cell culture chambers to be exposed to 64 different combinations of drugs 
A and B at 8 different dilutions each sequentially in a single experimental run.  Figure 
2.3(B) shows an individual cell culture chamber with HCT116-MKI67-1000 GFP 
colorectal cancer cells cultured inside.   
            This microfluidic device has been previously used in a study lead by our  
collaborator Kim et al. to probe the combinational effects of doxorubicin and TNF-
related apoptosis-inducing ligand (TRAIL) on PC3 prostate cancer cells [24].  We have 
further developed this microfluidic platform to overcome previous limitations in full 
automation capability and non-uniform cell seeding that influences the reliability of the 
on-chip assays.  First, a LabVIEW
TM
 interface was developed to control the microfluidic 
valve actuation and drug injection by controlling 4 pneumatic actuators and 2 syringe 
pumps simultaneously.  This enabled fully automated multi-day sequential cancer drug 
assay with periodic medium and drug replenishment (Figure 2.2).  To overcome non-
uniform cell seeding in each of the 64 cell culture chambers, four symmetric cell seeding 
ports connected to the cell culture chamber array was developed.  Together with the two 
outlets, this symmetric cell seeding scheme reduced the sidewall effect of single seeding 
port scheme, where much lower density of cells can be found near the channel sidewalls.  
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Figure 2.2.  Schematic diagram of the high-throughput combination drug 
treatment live cell array experimental setup.  A LabVIEW
TM
 interface controlled a 
multichannel microvalve controller and syringe pumps, enabling fully automatic multi-
day drug treatment assays. 
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Figure 2.3.  Images of the high-throughput live cell array microdevice for 
combination drug treatment assay.  (A) Array of 8 by 8 cell culture chambers 
(chamber size: 700 µm × 700 µm) are exposed to 64 pair-wise combinations of drugs A 
and B at different dilutions.  (B) Brightfield (left) and fluorescence (right) images of 
HCT116-MKI67-1000 GFP reporter colorectal cancer cells inside one of the cell culture 
chambers. 
(A) 
(B) (C) 
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The microfluidic platform is composed of two layers, the pneumatic control layer 
which contains pneumatic valves, and the fluidic layer which contains fluidic channels.  
The pneumatic valves used here are the normally closed microvalves.  Figure 2.4 shows 
the schematic of the normally closed valve.  When positive pressure was applied, the 
membrane in the valve region was bent down and the fluidic channels were blocked; on 
the contrary, when negative pressure was applied, membrane in the valve region was 
bent up and the fluidic channels were connected.  In natural state the membrane tends to 
bend down due to its elasticity, where positive pressure can be reduced or even removed 
if no fluid transportation is needed.  This scheme is especially suitable for cell culture 
and cell assay since the need for large pressure during incubation is eliminated, 
significantly reducing bubble generation during valve operation. 
The microfluidic cell culture platform was fabricated with 
poly(dimethylsiloxane) (PDMS, Sylgard 184, Dow Corning) using soft lithography [11] 
(Figure 2.5).  The soft lithography master molds for the microfluidic device were 
fabricated with standard photolithography processes.  For the fluidic layer, the silicon 
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Figure 2.4.  Schematic of the normally closed valve.  (A) When positive pressure is 
applied, the membrane in the valve region is bent down and the fluidic channels are 
blocked.  (B) When negative pressure is applied, membrane in the valve region is bent 
up and the fluidic channels are connected. 
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wafer was rinsed with acetone and IPA, and heated at 150°C for 10 min on a hot plate to 
vaporize the liquid, then negative photoresist SU-8 2050 (Microchem) was spincoated at 
1800 rpm for 50 sec, soft baked at 65°C for 20 min and 95°C for 40 min, exposed at the 
dosage of 220 mJ/cm
2
, yielding a 100 µm thick fluidic layer pattern.  For the pneumatic 
layer, the silicon wafer was rinsed with acetone and IPA, and heated at 150°C for 10 min 
on a hot plate, then negative photoresist SU-8 2050 (Microchem) was spincoated at 800 
rpm for 50 sec, soft baked at 65°C for 40 min and 95°C for 40 min, exposed at the 
dosage of 330 mJ/cm
2
, yielding a 200 µm thick fluidic layer. 
  Thereafter PDMS prepolymer and curing agent were prepared at 10:1 weight 
ratio, and degassed in a vacuum chamber for 1 h.  The control layer was casted to 5mm 
think, while the fluidic layer was spincoated at 700 rpm for 30 sec, yielding a 150 µm 
thick membrane. After curing in an 80°C oven for 2 h, the control layer and fluidic layer 
were bonded with oxygen plasma treatment (100 mTorr, 100W, 40 sec) by visual 
alignment.  The PDMS microfluidic device was finally bonded on a glass substrate with 
oxygen plasma treatment (100 mTorr, 100W, 40 sec). 
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Figure 2.5.  Illustration of the soft lithography process. 
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2.3.      Experimental 
The HCT116-MKI67-1000 GFP cell line was obtained from Translational 
Genomics Research Institute (Phoenix, AZ), and maintained with RPMI 1640 medium 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen) in a 5% CO2 
humidified incubator at 37°C.  Prior to microfluidic experiment, the cells were 
trypsinized and stained with Vybrant
®
 Dyecycle
TM
 violet live cell nuclei stain 
(Invitrogen) at 5 µM for 30 min as instructed. 
The assembled PDMS microfluidic device was thereby sterilized with UV, and 
coated with Collagen I (Invitrogen) to enhance cell attachment to the glass substrate.  
Cells were trypsinized, stained, and seeded via the four symmetric cell-seeding ports 
simultaneously with the syringe pump.  After 4 h of incubation to allow cells to settle 
down, phenol red-free and low riboflavin content culture medium M-199 (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) was refreshed every 4 h for 24 h, at 5 
µl/min flow rate for 3 min each time.  The phenol red-free and low riboflavin content 
culture medium was used to decrease background noise for fluorescence microscopy.  
This initial incubation time was then followed by sequential treatment with dilution 
gradients of two drugs Lapatinib and LY 294002 (LC Laboratories) using the same 
refreshing scheme for a total exposure time of 48 h.  The highest concentration of 
Lapatinib was optimized to 16 µM, while LY 294002 to 25 µM. 
Brightfield and fluorescence images were acquired with a Zeiss 200M inverted 
microscope using an AxioCam MRM Rev 2 camera (Carl Zeiss).  Thereafter 
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fluorescence images were analyzed with ImageJ (NIH).  The green fluorescent (GFP) 
channel was analyzed by measuring the sum of fluorescence intensity per cell area, 
while the blue fluorescence channel showing nuclei was analyzed by counting cell 
numbers. 
 
2.4.      Characterization of Cell Seeding Uniformity 
The four-port symmetric cell-seeding design improved the uniformity of cell 
seeding in the microfluidic device, which is an important parameter in parallel 
comparison studies.  Figure 2.6 shows images of cell culture chambers after seeding with 
the four symmetric port design (Figure 2.6(A)) and the single seeding port design 
(Figure 2.6(B)) at three different locations of the microdevice; near the seeding port 
(Figure 2.6 left images), near the center of the culture chamber array (Figure 2.6 middle 
images), and near the opposite position of the seeding port (Figure 2.6 right images).  
Three chambers in above mentioned locations were picked up and compared for cell 
seeding uniformity.  It can be clearly seen that the four symmetric seeding port scheme 
greatly enhanced cell seeding uniformity, with a uniform cell seeding density of 173±5.9 
cells/chamber (C.V. = 3.4%) compared to 122±51 cells/chamber (C.V. = 41.8%) as in 
the device with only one cell seeding port throughout the 64 cell-culture chambers. 
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Figure 2.6.  Improved cell seeding uniformity with symmetric seeding scheme 
design.  (A) Selected images of cell culture chambers at different locations showing 
non-uniform cell seeding with one seeding port. (B) Selected images of cell culture 
chambers at different locations showing uniform cell seeding with four symmetric 
seeding ports.  The arrays indicate cell seeding ports. 
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2.5.      Drug Effectiveness Analysis 
The microfluidic high-throughput screening platform was used to investigate the 
gene regulations of HCT116 colorectal cancer cells through combination therapies of 
cancer drug Lapatinib and kinase inhibitor LY 294002 in the sequential treatment 
fashion. 
The effectiveness of the drug treatment was analyzed in two different ways: 1) 
the inhibition of the proliferation using the MKI67-GFP promoter-reporter as an 
indicator of the proliferative activity and 2) the suppression of cell growth overtime. 
 
2.5.1.   Drug Treatment Analysis through GFP Expression 
In the first method, green fluorescence images were acquired and the sum of 
fluorescence intensity per cell area was measured with ImageJ.  The sum instead of the 
mean value of fluorescence intensity within each cell area was used in consideration of 
more accurately representing the total GFP expression status for each cell.  Since the 
cells are highly heterogeneous in a culture group, they differ significantly in cell shape, 
size, and cell cycle stages.  Therefore the sum of fluorescence intensity per cell area can 
be a more accurate representation of the total GFP reporter activity inside a cell than 
purely calculating the average fluorescence intensity.  Figure 2.7 shows the effectiveness 
of Lapatinib in reducing the proliferative activities of HCT116 cells using GFP reporter 
in the microdevice.  With the increasing concentration of the drug Lapatinib from 0 to 16 
μM, the total intensity of the green fluorescent signal decreased by 50%, indicating 
 24 
reduced proliferative activity.  The IC50 was 16 µM.  The result demonstrates efficacy 
of Lapatinib in reducing the proliferation, as well as the utility of using the microdevice 
in this cancer cell drug assay.  The result using the microfluidic platform was verified 
using a conventional 96-well plate study.  For the 96-well plate experiment, HCT116 
cells were seeded at 5E5 cells/ml, cultured for 12 h with M199, and then treated with 
different concentrations of Lapatinib for 48 h.  Figure 2.8 compares the result from the 
microfluidic platform to that of the 96-well plate, with Y-axis indicating the decrease in 
fluorescence intensity in response to increasing concentrations of Lapatinib.  Although 
some deviation was observed when comparing the microdevice result to the 96-well 
plate result, the general trend as well as IC50 matched well in both approaches, 
indicating the utility of the microdevice.  The deviations might come from the 
differences in cell culture environments, and effective drug concentration in these two 
platforms. 
 
 
 
 
 
 
 
 
 
 25 
 
20 μm
 
 
0
5
10
15
20
25
30
0 2.24 4.48 6.72 8.96 11.2 13.44 16
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 p
e
r 
c
e
ll
 
(a
.u
.)
Lapatinib concentration (µM)  
Figure 2.7.  The efficacy of Lapatinib in reducing the proliferation activity of 
HCT116 cells tagged with GFP reporter.  (A) Fluorescence images of the HCT116-
MKI67-1000 GFP cells after 48 h of Lapatinib treatment at 8 different concentrations.  
(B) The sum of fluorescence intensity per cell area versus Lapatinib concentrations. The 
drop in fluorescence intensity indicates the effectiveness of the drug. 
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Figure 2.8.  Fluorescence intensity fold change of the HCT116-MKI67-1000 GFP 
cells in both microfluidic device and microtiter plate after 48 h of Lapatinib 
treatment at 8 different concentrations. 
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2.5.2.   Individual Drug Treatment Analysis through Cell Growth Analysis 
The fluorescence signal from the GFP expression in HCT116 cells was extremely 
weak and the signal to noise ratio was only around 5.  This caused major problem in 
measuring the fluorescence intensity drop induced by drug treatment.  Therefore we 
developed an alternative method by monitoring cell growth rate change based on our 
observation.  In this method, cell growth rate change in response to different 
concentrations of Lapatinib and LY 294002 as well as combinations of these two drugs 
was analyzed.  Blue fluorescence images showing nuclei were acquired, and cell growth 
rates were calculated from the ratios of cell numbers in each chamber before and after 
drug treatment over 48 h.  Figure 2.9(A) and (B) show the normalized cell growth rate 
changes due to exposure to concentration gradients of Lapatinib and LY 294002.  In 
Figure 2.9(A), the cell growth rate decreased from 100% to 34% when exposed to 24 
μM of Lapatinib.  In Figure 2.9(B), the cell growth rate decreased from 100% to 21% 
when exposed to 25 μM of Lapatinib.  The IC50 for cell growth change with Lapatinib 
was 14 µM, while the IC50 with LY 294002 was 20 µM.  These results indicate the 
significance of cell growth activity affected by the application of the two drugs, which 
can be used as an indicator of the drug effectiveness.   
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Figure 2.9.  The growth rate change of HCT116 cells exposed to Lapatinib and LY 
294002 at concentration gradients.  (A) Cell growth rate change after 48 h of Lapatinib 
treatment at different concentrations ( , p < 0.05).  Sample size n = 5.  (B) Cell growth 
rate change after 48 h of LY 294002 treatment at different concentrations ( , p < 0.05).  
Sample size n = 7. 
(A) 
(B) 
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To validate the usage of cell growth monitoring with nuclei staining as an 
indicator of the drug efficacy, a comparison between GFP reporter expression and cell 
growth rate was performed.  Figure 2.10 compares cell responses to different 
concentrations of Lapatinib in terms of reduction in GFP intensity per cell and in terms 
of reduction in cell growth rate.  The two curves closely followed each other both in the 
trajectory and in the final effect, and the correlation coefficient of the growth rate change 
and fluorescence intensity change was 0.9921.  This strong correlation suggests that cell 
growth rate measurement can be used as a supplementary or alternative method in drug 
efficacy analysis. 
 
2.5.3.   Combination Drug Treatment Analysis through Cell Growth Analysis 
Based on the previous individual drug treatment analysis through cell growth rate 
monitoring, the utility of this growth rate analysis method was proved.  Therefore the 
combinational effect of Lapatinib and LY 294002 treatment was analyzed only using 
cell growth analysis so far as shown in Figure 2.11.  In this figure, Lapatinib alone (LY 
294002 concentration = 0 μM) caused 32.6% drop of HCT116 growth rate, while LY 
294002 alone (Lapatinib concentration = 0 μM) caused 76.5% drop of growth rate.  The 
added total effect of Lapatinib and LY 294002 is 109.1%, which is larger than 100%.  In 
combination, the maximum effect of the two drugs used together (Lapatinib 
concentration = 16 μM, and LY 294002 concentration = 25 μM) was 92%, suggesting 
that Lapatinib and LY 294002 are agonists and have additive effect when used together. 
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Figure 2.10.  The correlation of fluorescence intensity change and growth rate 
change in response to Lapatinib gradient treatment. 
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Figure 2.11.  HCT116-MKI67-1000 GFP cell growth rate change by combination 
treatment of Lapatinib and LY 294002. 
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To further clarify the dose response characteristics of each drug, concentration 
gradients of Lapatinib and LY 294002 were plotted against each other in Figure 2.12.  In 
both Figure 2.12(A) & (B), the weighted black lines refer to the control group (LY 
294002 concentration = 0 μM as in Figure 2.12(A), and Lapatinib concentration = 0 μM 
as in Figure 2.12(B)).  In Figure 2.12(A), the HCT116 growth rate dropped 23% in the 
control group, while 80% at most where LY 294002 concentration = 18 μM.  The linear 
regression slope for control is -1.4, while for the maximum effect concentration of LY 
294002 (18 μM) is -4.1.  In Figure 2.12(B), the HCT116 growth rate dropped 77% in the 
control group, while 88% at most where Lapatinib concentration = 16 μM.  The linear 
regression slope for control is -2.9, while for the maximum effect concentration of 
Lapatinib (16 μM) is -4.2.  The results here suggest that Lapatinib and LY 294002 
worked in agonism in the cell growth regulation of HCT116 cells. 
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Figure 2.12.  Combination effect of Lapatinib and LY 294002 in growth rate change 
of HCT116 cells.  (A) Growth rate change by concentration gradient of LY 294002 
plotted against that of Lapatinib. (B) Growth rate change by concentration gradient of 
Lapatinib plotted against that of LY294002. 
(A) 
(B) 
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2.6.      Conclusions 
Overall, we have successfully developed a fully automated high-throughput 
combination drug screening microfluidic live cell array with high cell seeding uniformity 
and utilized the platform for combinatorial gene regulation studies.  This high-
throughput screening system can be used to investigate combinational drug treatment 
effects at various concentration mixtures as well as drug dosing schemes in a sequential 
manner, all in high-throughput.  We expect that this system can greatly improve the 
efficiency in finding new combination cancer therapies. 
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CHAPTER III 
MICROFLUIDIC GEOMETRIC METERING-BASED LIVE CELL  
TOXIN SCREENING PLATFORM 
 
3.1.      Introduction 
The microfluidic network-based gradient generator discussed in Chapter II is 
most widely used in high-throughput screening where generating complex gradient 
profiles or mixtures are needed.  Such profiles and mixing ratios are determined by the 
microchannel network design.  However, this method has many practical limitations for 
routine use since the generated gradient profiles or chemical mixing ratios rely on the 
stable flow at optimized flow rate throughout the experiment.  In applications requiring 
multi-day drug or toxin treatments against cells, this configuration of gradient generator 
suffers from lack of long-term stability throughout the experiment, difficulties in 
repeatedly generating exactly the same profiles from run to run, consumption of large 
amount of reagents due to continuous flow, and subjecting cells to unwanted and 
potentially damaging shear stresses, which all make it challenging for routine use.  Also, 
small variation in devices stemming from microfabrication may results in different 
device to device gradient profiles.  Even though such changes and variations are easy to 
identify when characterizing devices with color dye or fluorescent dye, once these 
devices are used in routine, knowing the actual generated concentrations is impossible.  
Thus, generating reliable and repeatable concentrations and mixtures from run to run 
over the entire period of assay as well as from device to device becomes extremely 
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important.  It is also difficult to implement mixing of three or more reagents with 
dilutions of choice unless complex microfluidic structures or dynamic control schemes 
are used. 
The need for generating multi-reagent mixtures on-demand in a microfluidic live 
cell assay device can be satisfied by implementing a geometric metering approach where 
the mixing ratio is solely determined by the volume ratios of reagent chambers to be 
mixed.  This microfluidic geometric metering approach was first demonstrated by Carl 
Hansen, et al., as a robust, scalable and accurate microfluidic metering method and was 
termed as barrier interface metering (BIM) [25].  The geometric metering method is 
shown in Figure 3.1.  The principle is to partition sections of the microfluidic channel at 
well-defined volumes and fill them separately with different solutions.  These 
geometrically defined sections can be isolated from the microfluidic channels and mixed 
with other adjacent sections by actuating pneumatic control microvalves.  The power and 
flexibility of this metering scheme was demonstrated with ultra-small volume screening 
of protein crystallization conditions, which is a major hurdle in structural biology efforts.  
However, the scheme illustrated here is limited to mixing only by adjacent chambers,  
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and no delivery of mixture solution was performed.  In order to utilize this method in 
producing multi-reagent mixtures at specified mixing ratios and apply them to arrays of 
cell culture chambers for high-through live cell assay, robust and accurate fluid 
transportation method has to be also implemented.   
Therefore, a novel method called pressurized membrane pumping (PMP) for 
robust, intact, and accurate fluid transportation in microfluidic systems was developed.  
Overall, we developed a geometric metering-based microfluidic concentration mixture 
generator capable of generating 64 mixtures of three reagents with four different 
concentrations for each, integrated with a 64-cell culture chamber array for combination 
environmental toxin screening.  The cell culture chambers have arrays of single cell 
trapping sites to allow single cell resolution analysis of expression profile in response to 
the stimuli.  The functionality as a microfluidic live cell environmental toxin screening 
platform of the developed integrated geometric metering-based mixture generator and 
cell culture chamber array was demonstrated. 
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Figure 3.1.  Geometric metering schematic (reproduced from [25]).  Control 
channels are shown in orange, while fluidic channels are shown in blue.  Reagents A and 
B can be filled separately by opening the top and bottom microvalves while closing the 
middle microvalve.  Thereafter, reagents A and B can be mixing by diffusion when the 
middle microvalve is open while the top and bottom microvalves are closed.  
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3.2.      Design and Fabrication 
3.2.1.   Overview 
            Figure 3.2(A) shows an 8-channel prototype version of the developed 
microfluidic geometric metering-based combination environmental toxin single cell 
screening platform.  The device is composed of six functional components: reagent 
chambers; pressurized membrane pumping fluid delivery system; mixing chambers; cell 
culture chambers with and without single cell trapping array; cell seeding channels on 
the pneumatic control layer; and pneumatic valves.  Of them, buffer reservoirs, 
reagent/mixing/cell culture chambers were all geometrically predefined. 
            The workflow of the developed system goes as follows.  Buffer is filled into the 
buffer reservoirs, while reagents are filled into each reagent metering chambers.  
Thereafter the reagents are delivered into downstream mixing chambers by actuating the 
pneumatic buffer reservoir membrane valves, and allow diffusive mixing.  The generated 
mixtures are then delivered to cell culture chambers by again actuating the buffer 
reservoir membrane valve. 
 
3.2.2.   Geometric Metering-based Concentration Mixture Generator 
            The developed geometric metering-based concentration mixture generator is 
capable of generating combinatorial mixtures of 3 environmental toxins each having 4 
different concentrations (full capability 4
3 
 = 64 conditions).  It can produce robust and 
repeatable multi-reagent mixtures on-demand at significantly reduced reagent 
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consumption (1/700 compared to serpentine type gradient generator over a 2-day 
experiment).  Figure 3.2(B) shows the schematic of the principle of geometric metering-
based mixture generator with fluid delivery capability for live cell assay, where two 
different concentrations of both reagents A and B are mixed combinatorially, generating 
4 unique mixtures (2 by 2).  Reagents A and B were each filled into rows of reagent 
chambers with two different volumes, and were subsequently driven into the 
downstream mixing chambers.  Here the dilution and mixing ratios are “hard-wired” into 
the platform by specifying volume ratios between reagent chambers.  In the 8-channel 
prototype shown in Figure 3.2(A), the three reagent channels (red, yellow, green) run 
perpendicular to the main flow channels and are separated from each other through 
pneumatically actuated microvalves. Each reagent channel has series of chambers of 
four different sizes (2.4, 4.8, 7.2, 9.6 nl), and all three of them are filled simultaneously 
using separate reagent-loaded syringes.  These chambers are positioned in each reagent 
channel so that combinatorial mixing can be realized. 
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Figure 3.2.  The microfluidic geometric metering-based mixture generator 
integrated with cell culture array.  (A) The fluidic layer with magnified view of the 
functional regions.  (B) Schematic of the principle of geometric metering-based mixture 
generation.  Two reagents (A and B) were filled into reagent chambers at specified 
volumes and driven into mixing chambers for diffusive mixing, facilitating on-demand 
multi-reagent mixture generation.  (C) Overall image of the fabricated device.  
Combinations of 4 different chamber sizes for reagents A (blue), B (red), and buffer 
(yellow) on each column generate combinatorial mixtures of 4 different dilutions of A, 
and B when pushed into the mixing chambers through pneumatic buffer reservoir 
membrane valve actuation.  The pink colors indicates cell seeding path. 
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3.2.3.   Pressurized Membrane Pumping 
            The so called pressurized membrane pumping (PMP) method utilizes the 
mechanical and structural characteristics of the PDMS multilayer microfluidic device, 
and introduces the pneumatic pressure as pumping power source.  The PDMS 
microfluidic device developed for this high-throughput toxin screening consists of three 
layers: the thick pneumatic control layer, the fluidic membrane layer, and the glass 
substrate.  The fluidic membrane layer is about 100 μm thick and has a channel height of 
30 μm, and pneumatic pressure is introduced into the buffer reservoir membrane valve 
which is prefilled with DI water to prevent bubble generation during valve actuations.  
When positive pressure is applied to the membrane valve, at the same time the inlet 
valve is closed and the outlet valve is open, the membrane valve is bent down and 
solutions inside the buffer reservoir will be pumped out. On the contrary, when positive 
pressure is removed, at the same time the inlet valve is open and the outlet valve is 
closed, the membrane valve is open and the buffer reservoir will be refilled (Figure 3.3).  
The buffer reservoirs were designed with a specific volume (34 nl) to precisely deliver 
all three reagents into downstream mixing chambers through a single actuation of the 
membrane valve.  The residue leftover in the buffer reservoir is negligible with this 
pumping method due to relative geometries of membrane thickness and channel height, 
as well as the pneumatic pressure applied. 
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Figure 3.3.  Pressurized membrane pumping.  (A) Solutions driven into the buffer 
reservoir by actuating inlet and outlet valves.  (B) Positive pressure bends down the 
membrane valve, solutions driven out of the buffer reservoir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
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            Using this scheme, there is no need to precisely time the opening and closure of 
the microvalves at the mixing chambers as well as the injection time for buffer syringe 
pump in order to completely trap reagents inside the mixing chambers. 
 
3.2.4.   Diffusive Mixing and Cell Seeding 
Diffusive mixing of reagents inside the mixing chambers was employed, since 
reagent mixtures typically needed to be generated only every 4 hours throughout the 
multi-day experiment.  Supporting pillars were added to the mixing chambers to prevent 
chamber collapse during device bonding.  Cell culture chambers are located downstream 
of these mixing chambers, and the overall channel height is 30 µm.  Cell culture 
chambers were designed both with single cell traps and without.  In each cell culture 
chamber with single cell traps, more than 200 hydrodynamic trapping structures were 
designed into an asymmetric array with lateral displacements between neighboring rows 
to maximize the trapping efficiency (Figure 3.4(A)).  The cell traps are hanging from the 
channel top so that the traps are elevated from the channel bottom with a 3 µm gap.  For 
both kinds of cell culture chambers, each chamber has cell seeding via holes connected 
to a single cell seeding port on the pneumatic layer so that cells can be loaded directly 
into the cell culture chambers simultaneously (Figure 3.4(B)).  Two side-channels with 
high fluidic resistance were implemented near the cell seeding channels to overcome the 
sidewall effect, ensuring uniform cell seeding into all eight culture chambers.  The 
overall image of the fabricated device is shown in Figure 3.2(C).   
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Figure 3.4.  Single cell seeding and trapping.  (A) Schematic of the cell seeding.  (B) 
Asymmetric single cell trapping array with lateral displacement between neighboring 
rows inside one cell culture chamber.  The enlarged inset shows the geometry of a single 
cell trap. 
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3.2.5.   Device Fabrication 
The device was fabricated with poly(dimethylsiloxane) (PDMS, Sylgard 184, 
Dow Corning), and coated with fibronectin for enhanced cell attachment before cell 
loading.  The pneumatic control layer is fabricated by cast molding a thick layer of 
PDMS, and the fluidic membrane layer is fabricated by spin coating PDMS at 700 rpm 
for 40 s.  Thereafter the two layers were bonded with oxygen plasma treatment and via 
holes were made by stainless steel punches.  The assembled PDMS block was finally 
bonded to glass substrate using oxygen plasma treatment. 
 
3.3.      Experimental 
The functionality of the geometric metering-based mixture generator was first 
characterized with color dyes.  For the opening and closure of general pneumatic valves, 
7 psi positive pressure and -2 psi negative pressure were used.  While for the buffer 
reservoir membrane valve, 3 psi positive pressure was used for pumping out buffer 
solution for reduced flow rate and improved controllability and robustness.  The run to 
run and device to device repeatability of the developed geometric metering-based 
microfluidic multi-reagent mixer and the network-based gradient generator was 
characterized with fluorescein isothiocyanate (FITC) and rhodamine B isothiocyanate 
(RBITC) in comparison.  The network-based gradient generator used here consists of a 
dual-inlet gradient generator and corresponding eight downstream chambers (Figure 
2.1).  FITC and DI water were injected at the same flow rate (1 μl/min) via two inlets, 
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and the repeatability was characterized by measuring the fluorescence intensity in eight 
branching chambers after a 5-minute period for the flow to stabilize.  The geometric 
metering-based mixer used here is a simplified version of Figure 3.2(C) which removes 
the cell seeding section.  RBITC was filled into reagent chambers with a syringe pump, 
and driven into mixing chambers subsequently.  The diffusive mixing took place after 
within 4 h period in the 37°C incubator, and the mixing process was characterized at 
near inlet, middle, near outlet locations of each mixing chamber by measuring 
fluorescence intensities. 
After characterization of the developed platform, the effect of potent atmospheric 
pollutants polyaromatic hydrocarbon (PAH) pyrene on regulating gene expression in rat 
hepatoma (H4IIE) cells with eGFP reporter was studied on the cell population level.  
Though only pyrene treatment was demonstrated, the device is fully capable of PAH 
mixture treatment as shown in the previous geometric metering-based mixture generator 
section.  H4IIE cells were seeded via the cell seeding port on the pneumatic layer 
(Figure 3.2(C)), flowing into the fluidic layer via through holes, and trapped inside the 
cell culture chambers.  After the cells attached to the substrate, different concentrations 
of pyrene solutions were applied to each cell culture chamber every 4 h, for a total 
treatment time of 24 h.  All operations were automatically controlled by a Labview
®
 
interface, enabling fully automated 2-day screening experiment.  Fluorescence images 
were acquired with a Zeiss 200M inverted microscope using an AxioCam MRM Rev 2 
camera (Carl Zeiss) and analyzed with ImageJ (NIH) by measuring the sum of 
fluorescence intensity per cell area. 
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Single cell trapping and culture have been first tested with a simplified one 
channel cell seeding and culture scheme (Figure 3.5(A)), and then performed with the 
developed geometric metering-based live cell assay platform where the cell seeding port 
and micropillar filter were placed on the pneumatic layer.  The micropillar filter was 
implemented to exclude extra cellular matrix materials and conjugated multiple cells.  
Microvalves can isolate the single cell array from cell seeding and medium supply ports, 
efficiently eliminating floating cell migration from cell seeding channel and micropillar 
filter, as well as continuous perfusion of medium caused by pressure residue after 
stopping medium injection.  Supporting pillars were introduced to cell culture chambers 
to maintain the 3 μm gap between channel bottom and single cell traps.  The cell 
handling procedures were the same as the population-based cell seeding and culture.  
Cell culture was performed in two ways.  In one method, the microfluidic device was 
tilted at 20° to maintain cell position inside a 37°C, 5% CO2 incubator for cell 
attachment.  In another approach, perfusion of culture medium was applied after seeding 
to keep cells with hydrodynamic pressure.  With the perfusion method, the seeded H4IIE 
cells were cultured inside a Zeiss Axiovert 200M microscope incubator (Carl Zeiss). 
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Figure 3.5.  Single cell trapping and culture device.   
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3.4.      Results and Discussion 
3.4.1.   Functionality Validation 
Figure 3.6 shows the operation procedures of the developed geometric metering 
concentration mixture generator device.  From left to right, buffer injection, reagent 
injection, reagent delivery by pressurized membrane pumping into mixing chambers, 
diffusive mixing, mixture delivery into cell culture chambers, and mixture regeneration 
were all successfully demonstrated with color dyes. 
Diffusive mixing was slow in the mixing chambers due to extended chamber 
length (4.5 mm).  However, the increased ambient temperature in the cell culture 
incubator (37°C) allowed complete mixing to take place within a 4 h period, which is 
enough for periodic medium or toxin replenishment in the cell culture chambers (Figure 
3.7). 
One issue with the above experiments was that the solutions in different channels 
were delivered at different paces with the pressurized membrane pumping.  This is 
because of the unequalized fluidic resistances in different channels, and can be solved by 
introducing compensating serpentine timing channels between buffer reservoirs and 
reagent chambers (Figure 3.8).  With the timing channels, not only the fluid delivery 
uniformity was improved, but also robustness of the pressurized membrane pumping 
method was enhanced. 
 
 51 
 
Buffer 
reservoirs
Reagent 
chambers
Mixing 
chambers
Cell culture 
chambers
Syringe 
pump
Reagents 
injection
Reagents 
delivery
Diffusive 
mixing
Mixture 
delivery
Mixture 
regeneration
 
Figure 3.6.  Working procedures of the geometric metering-based mixture 
generator.  (A) Pre-filling the whole device with buffer first (yellow), followed by 
reagent loading into the corresponding chambers (red, yellow, blue).  (B) Driving 
reagents into the mixing chambers by pressurized membrane pumping.  (C) Diffusive 
mixing of the reagents.  (D) Delivering generated mixtures into each cell culture 
chamber.  (E) Regeneration of reagent mixtures. 
 
(A) (B) (C) (D) (E) 
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Figure 3.7.  Timelapse images showing the diffusive mixing process in the 37°C 
incubator.  
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w/o timing channels w/ timing channels
 
Figure 3.8.  Comparison of the uniformity of reagents delivery into mixing 
chambers by pneumatically actuating the buffer reservoirs microvalves.  (A) Non-
uniform reagent delivery in the absence of timing channels.  (B) Uniform reagent 
delivery when using timing channels. 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
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3.4.2.   Repeatability Comparison 
The run to run and device to device repeatability was compared with FITC and 
RBITC between microfluidic network-based gradient generator and the geometric 
metering-based concentration mixture generator (Figures 3.9 & 3.10).  Figure 3.9 shows 
the run-to-run normalized fluorescence intensity profiles among different channels in the 
network-based gradient generator and geometric metering-based mixture generator with 
3 repeats each.  Figure 3.10 shows the device-to-device normalized fluorescence 
intensity profiles in the network-based gradient generators and geometric metering-based 
mixture generators with 3 repeats each.  From run-to-run, the geometric metering-based 
mixture generator showed obvious improvement in repeatability with 10% coefficient of 
variance (C.V.) compared to C.V. = 22% of the network-based gradient generator.  From 
device-to-device, the geometric metering-based mixture generator again showed 
significant improvement in repeatability with C.V. = 6% compared to C.V. = 20% of the 
network-based gradient generator.  This significant improvement of repeatability stems 
from the static mixture generation and fluid delivery nature of geometric metering-based 
mixture generator compared to the dynamic continuous flow mixing characteristic of the 
conventional network-based gradient generator. 
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Figure 3.9.  Run-to-run comparison of the repeatability of the network-based 
gradient generator and the geometric metering-based mixture generator.  (A) 
Normalized fluorescence intensity profile in the network-based gradient generator with 3 
repeats, showing large standard deviation.  (B) Normalized fluorescence intensity profile 
of different channels having different reagent chambers of the geometric metering-based 
mixture generator with 3 repeats, showing the small standard deviation. 
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Figure 3.10.  Device-to-device comparison of the repeatability of the network-based 
gradient generator and the geometric metering-based mixture generator.  (A) 
Normalized fluorescence intensity profile in the network-based gradient generators (n = 
3), showing large standard deviation.  (B) Normalized fluorescence intensity profile of 
different channels having different reagent chambers of the geometric metering-based 
mixture generators (n = 3), showing the small standard deviation. 
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3.4.3.   Environmental Toxin Screening 
Polyaromatic hydrocarbons (PAHs) are potent atmospheric pollutants, which are 
carcinogenic, mutagenic, and teratogenic.  PAHs are typically generated by incomplete 
combustion, and can also come from cooking meat at high temperatures.  PAHs exhibit 
concentration-dependent toxicity effect to human and animal cells, and the toxicities of 
individual molecules have been studied intensively.  However, PAHs typically come in 
the form of mixtures of isomers, causing great difficulties in understanding and 
determining the concentration-dependent mixture interactions.  This kind of study 
requires high-throughput and robust screening against a large range of concentration 
mixtures of multi-reagents, which is difficult to be achieved by the conventional 
network-based gradient generators.  Our developed geometric metering-based mixture 
generator can be utilized for such systematic investigations of the interaction patterns of 
PAHs mixtures in a high-throughput fashion. 
As the functionality and repeatability performance were characterized with color 
dyes and fluorescent dyes, we implemented this method into environmental toxin 
screening of rat hepatoma (H4IIE) cells.  The comparison of repeated experiment results  
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between three different live cell screening methods further validated the utility of this 
developed geometric metering-based concentration mixture generator device.  
Environmental toxin pyrene was applied to GFP tagged H4IIE cells cultured in the 24-
well plate, microfluidic network-based gradient generator device, and the developed 
geometric metering-based mixture generator device at different concentrations, 
respectively,  with three repeats each.  Figure 3.11 clearly shows that the C.V. of the 
geometric metering-based device (5%) was much closer to that of standard 24-well plate 
results (3%), while the C.V. of network-based device was much larger (12%).  However, 
one drawback of the geometric metering-based device is the lack of control 
(concentration = 0), therefore in Figure 3.11(A) & (B), the normalized fluorescence 
intensity change for pyrene concentration = 1.25 μM was adjusted for the convenience 
of comparison between standard deviations. 
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Figure 3.11.  Comparison of the repeatability with pyrene treatment of H4IIE cells 
between the network-based gradient generator, the geometric metering-based 
mixture generator, and the microtiter plate.  (A) Comparison of the repeatability of 
pyrene treatment between the microtiter plate and the geometric metering-based mixture 
generator (n = 3).  (B) Comparison of the repeatability of pyrene treatment between the 
network-based gradient generator and the geometric metering-based mixture generator 
(n = 3).  The normalized fluorescence intensity of pyrene concentration = 1.25 μM was 
adjusted for the convenience of comparison between standard deviations. 
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3.4.4.   Single Cell Trapping and Culture 
The developed asymmetric hydrodynamic single cell trapping array with lateral 
displacements between neighboring rows significantly improved the trapping efficiency.  
The optimized trap geometry as well as the reduced channel height improved the 
selectivity of single cells over two or multiple cells to be trapped.  This optimized design 
resulted in single cell seeding efficiency of 80%, with the remaining 10% of traps having 
two cells and 5% having multiple cells, and with 5% vacancy (Figure 3.12(A)).  The cell 
attachment and culture by tilting the microfluidic device at 10° inside a 37°C, 5% CO2 
incubator was shown in Figure 3.12(B).  In the perfusion method, the seeded H4IIE cells 
were cultured inside a Zeiss Axiovert 200M microscope incubator (Carl Zeiss).  Cell 
attachment, growth, and part of dividing were observed by timelapse imaging (Figure 
3.12(C)). 
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Figure 3.12.  Hydrodynamic single cell trapping and culture.  (A) Single cell seeding 
result with the developed hydrodynamic trapping scheme.  (B) Cell attachment after 3 h 
of incubation tilted at 10°.  (C) Timelapse images showing a single cell trapping, 
attaching, growing, and dividing with perfusion flow in a Zeiss Axiovert 200M 
microscope incubator. 
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CHAPTER IV 
CONCLUSION AND FUTURE WORK 
 
4.1.      Conclusion 
In this thesis, robust and high-throughput microfluidic mixture generation 
devices were developed and utilized for combination live cell screening versus drugs and 
toxins. 
A microfluidic network-based gradient generator capable of producing pair-
wised gradient profile of two drugs was integrated with a 8 by 8 cell culture array for the 
study of synergistic effect of cancer drug Lapatinib and kinase inhibitor LY 294002 on 
humane colorectal cancer cell HCT116 tagged with MKI67-GFP promoter-reporter 
group.  Symmetric cell seeding channels improved the uniformity of cell seeding.  Both 
GFP reporter activity and cell growth rate were recorded and used as the measures to 
evaluate the drug effects, and strong correlation between these two methods was 
observed.  Synergy was reported with sequential treatment of the two drugs by 
measuring cell growth rate change. 
However, due to the limitations of this network-based mixer in large reagent 
consumption, continuous stable flow requirement, and subjecting cells to shear stresses, 
a novel microfluidic mixer which implemented the geometric metering approach was 
developed.  This geometric metering method is inherently little reagent consumption, 
robust and scalable since the mixing ratio is solely dependent on the volumes of reagent 
chambers.  A novel and straightforward microfluidic fluid delivery method called 
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pressurized membrane pumping (PMP) was developed and integrated with the geometric 
metering method to build a fully functional robust and high-throughput microfluidic cell 
culture and toxin screening platform.  Though only a prototype 8-channel device was 
demonstrated for functionality, this scheme can be readily transformed into large scale 
screening platform due to the intrinsic scalability of geometric metering method.  This 
device showed improved repeatability over conventional network-based gradient 
generator.  The effect of potent atmospheric pollutants polyaromatic hydrocarbon (PAH) 
mixtures (Pyrene, Benzo(a)Pyrene, and 20-Methylcholanthrene (20-MCA)) on 
regulating gene expression in rat hepatoma cells (H4IIE) with eGFP reporter was 
studied. 
 
4.2.      Future Work 
Single cell assay not only pushes the resolution to an individual cell level, but 
also offers enormous potentials in studying cell heterogeneity and sub-cellular processes.  
Single cell trapping enables easy tracking/analysis of single cell level gene expression, 
which provides quantitative information on the heterogeneous behaviors of individual 
cells not obtainable through population-based studies.  Hydrodynamic trapping of 
individual cells with physical obstacles offers a simple, effective, and physiologically 
favorable solution for separating single cells.   
The developed single cell trapping and culture method will be integrated with the 
developed geometric metering-based microfluidic live cell screening platform to 
quantitatively measure the heterogeneity of cell behaviors in response to combination 
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toxin treatment, and provide the first-hand data for studying gene expression regulation 
at the single cell level in a high-throughput fashion.  We believe this advancement will 
offer the flexibility of cell microenvironment control by varying environmental stimuli, 
while maintaining high-throughput capability. 
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APPENDIX A 
MASK DESIGN: ALIGNMENT MARK 
 
 
Figure A.1.  Mask layout of the alignment mark (alignment mark.dwg). 
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MASK DESIGN: FLUIDIC LAYER WITHOUT SINGLE CELL ARRAY 
 
 
Figure A.2.  Mask layout of the fluidic layer without single cell array (fluidic layer 
without single cell array.dwg). 
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MASK DESIGN: FLUIDIC LAYER WITH SINGLE CELL ARRAY 
 
 
Figure A.3.  Mask layout of the fluidic layer with single cell array (fluidic layer with 
single cell array.dwg). 
 
 
Single cell array 
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MASK DESIGN: PNEUMATIC LAYER 
 
 
Figure A.4.  Mask layout of the pneumatic layer (pneumatic layer.dwg). 
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APPENDIX B 
MASTER FABRICATION PROCEDURE 
 
B.1.   Aluminum Alignment Mark Patterning Procedure 
1. Clean the 3 inch silicon wafer with acetone, IPA, and DI water in sequence 
and dry with N2 gas 
2. Dehydrate baking at 200°C for 10 minutes 
3. Deposit Al layer using an E-beam evaporator to a thickness of 2000 Å 
4. Repeat steps 1 and 2 
5. Spin coat Microposit S1818 photoresist (Rohm and Haas Electronic Material 
LLC, Marlborough, MA) on the silicon wafer at 4000 rpm for 30 seconds with an 
acceleration time of 5 seconds 
6. Soft baking at 95°C for 10 minutes, cool down 
7. Expose UV using a mask aligner (MJB3, SUSS MicroTec Inc., Waterbury 
Center, VT) at 12 mW/cm
2
 (wavelength: 320 nm) for 14 second with a photomask 
having alignment marks 
8. Develop the pattern using MF-319 developer (Rohm and Haas Electronic 
Material LLC, Marlborough, MA) for 20-40 seconds 
9. Rinse in DI water and dry with N2 gas.  Only the alignment marks were 
covered with photoresist 
10. Etch uncovered Aluminum with Aluminum etchant for about 20 min 
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11. Rinse the wafer with acetone, IPA, and DI water in sequence, and dry with 
N2 gas 
 
B.2.   Fluidic Layer with Single Cell Trapping Array Master Fabrication Procedure 
1. Rinse the alignment mark patterned silicon wafer with acetone, IPA, and DI 
water in sequence, and dry with N2 gas 
2. Dehydrate baking at 200°C for 10 minutes 
3. Spin coat 3 μm thick photoresist (SU-8TM 2002, Microchem, Inc., Newton, 
MA) on the alignment mark pattered silicon wafer at 750 rpm for 40 seconds 
4. Soft baking at 95°C hotplate for 5 minutes, cool down 
5. Expose UV using a mask aligner (MA6, SUSS MicroTec Inc., Waterbury 
Center, VT) at 120 mJ/cm
2
 with the fluidic layer photomask which has single cell array 
6. Post exposure baking at 95°C for 6 minutes, cool down 
7. Develop the patterns using Microposit Thinner Type P (Shipley Co., 
Marlborough, MA) for about 30 seconds 
8. Rinse with IPA and DI water, and dry with N2 gas 
9. Spin coat 27 μm thick photoresist (SU-8TM 2025, Microchem, Inc., Newton, 
MA) on the pre- pattered silicon wafer at 3500 rpm for 40 seconds 
10. Soft baking at 65°C for 5 minutes, followed by 95°C baking for 10 minutes, 
cool down 
11. Expose UV using a mask aligner (MA6, SUSS MicroTec Inc., Waterbury 
Center, VT) at 180 mJ/cm
2
 with the fluidic layer photomask 
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12. Post exposure baking at 65°C for 3 minutes, followed by 95°C baking for 10 
minutes, cool down 
13. Develop the patterns using Microposit Thinner Type P (Shipley Co., 
Marlborough, MA) for about 3 minutes 
14. Rinse with IPA and DI water, and dry with N2 gas 
 
B.3.   Fluidic Layer without Single Cell Trapping Array Master Fabrication 
Procedure 
1. Rinse a bare 3 inch silicon wafer with acetone, IPA, and DI water in sequence, 
and dry with N2 gas 
2. Dehydrate baking at 200°C for 10 minutes 
3. Spin coat 30 μm thick photoresist (SU-8TM 2025, Microchem, Inc., Newton, 
MA) on the pre- pattered silicon wafer at 3000 rpm for 40 seconds 
4. Soft baking at 65°C for 5 minutes, followed by 95°C baking for 10 minutes, 
cool down 
5. Expose UV using a mask aligner (MA6, SUSS MicroTec Inc., Waterbury 
Center, VT) at 200 mJ/cm
2
 with the fluidic layer photomask which doesn‟t have single 
cell array 
6. Post exposure baking at 65°C for 3 minutes, followed by 95°C baking for 10 
minutes, cool down 
7. Develop the patterns using Microposit Thinner Type P (Shipley Co., 
Marlborough, MA) for about 3 minutes 
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8. Rinse with IPA and DI water, and dry with N2 gas 
 
B.4.   Pneumatic Layer Master Fabrication Procedure 
1. Rinse a bare 3 inch silicon wafer with acetone, IPA, and DI water in sequence, 
and dry with N2 gas 
2. Dehydrate baking at 200°C for 10 minutes 
3. Spin coat 120 μm thick photoresist (SU-8TM 2050, Microchem, Inc., Newton, 
MA) on the pre- pattered silicon wafer at 800 rpm for 40 seconds 
4. Soft baking at 65°C for 10 minutes, followed by 95°C baking for 45 minutes, 
cool down 
5. Expose UV using a mask aligner (MA6, SUSS MicroTec Inc., Waterbury 
Center, VT) at 250 mJ/cm
2
 with the pneumatic layer photomask 
6. Post exposure baking at 65°C for 10 minutes, followed by 95°C baking for 40 
minutes, cool down 
7. Develop the patterns using Microposit Thinner Type P (Shipley Co., 
Marlborough, MA) for about 5 minutes 
8. Rinse with IPA and DI water, and dry with N2 gas 
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APPENDIX C 
PDMS DEVICE FABRICATION PROCEDURE 
 
C.1.   Fluidic Layer PDMS Membrane Fabrication Procedure 
1. Place the fabricated fluidic layer master mold wafers inside the desiccator 
together with a weight boat containing 6 ~ 7 drops of tridecafluoro-1,1,2,2-
tetrahydrooctyl (trichlorosilane, United Chemical Technologies, Inc., Bristol, PA) 
2. Vacuum the desiccator for 10 min to allow trichlorosilane vaporize and evenly 
sprayed over the wafers 
3. Mix PDMS (Sylgard® 184, Dow Corning, Inc., Midland, MI) prepolymer with 
curing agent at 10 : 1 ratio, and degas in a desiccator for 10 minutes 
4. Pour the degassed PDMS prepolymer mixture onto trichlorosilane coated 
master wafers for 3 g per 3 inch wafer, and degas again in the desiccator for 10 min 
5. Spin coat at 700 rpm for 30 seconds 
6. Cure in an 85°C oven for 2 h 
 
C.2.   Pneumatic Layer PDMS Block Fabrication Procedure 
1. Place the fabricated pneumatic layer master mold wafers inside the desiccator 
together with a weight boat containing 6 ~ 7 drops of tridecafluoro-1,1,2,2-
tetrahydrooctyl (trichlorosilane, United Chemical Technologies, Inc., Bristol, PA) 
2. Vacuum the desiccator for 10 min to allow trichlorosilane vaporize and evenly 
sprayed over the wafers 
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3. Mix PDMS (Sylgard® 184, Dow Corning, Inc., Midland, MI) prepolymer with 
curing agent at 10 : 1 ratio, and degas in a desiccator for 10 minutes 
4. Pour the degassed PDMS prepolymer mixture onto trichlorosilane coated 
master wafers for 20 g per 3 inch wafer, and degas again in the desiccator for 30 min 
5. Cure in an 85°C oven for 2 h 
 
C.3.   PDMS Device Bonding 
1. Peel off the cured PDMS fluidic layer membrane and pneumatic layer block 
2. Punch holes in the pneumatic layer block with a gauge 19 needle 
3. Open via holes on the fluidic layer membrane with a sharp tweezer 
4. Apply oxygen plasma treatment (100 mTorr, 100W, 40 sec) for both fluidic 
layer membrane and pneumatic layer block, visually align under a stereo microscope 
5. Bake on a 80°C hotplate for 8 h 
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APPENDIX D 
CELL CULTURE PROTOCOL 
 
D.1.   Materials and Reagents 
[HCT116-MKI67-1000 GFP] (RPMI 1640) 
1 L: RPMI 1640 medium: RPMI 1640 (Invitrogen, Catalog number: 11875-085) 
with 10% Fetal Bovine Serum (Invitrogen, Catalog number: 16000-044), 20 mM 
HEPES (Invitrogen, Catalog number: 15630-080), 2-4 mM additional L-
Glutamine and 100 units/ml of Penicillin/Streptomycin (equivalent to 10ml 
Penicillin-Streptomycin-Glutamine (100X), liquid, Invitrogen, Catalog number: 
10378-016) 
(all given numbers are the final concentration) 
 
[H4IIE] (ALPHA-MEM) 
500 ml: 5 g MEM/ALPHA (Thermo Scientific Hyclone, Catalog number: 
SH30007.03), added into 425 ml ultrapure water from Milli-Q water purification 
system (Millipore), 1.755 g D-glucose (Fisher Scientific, Catalog number: 
BP350-1), 1.1 g Sodium Bicarbonate for 5% CO2 (VWR, Catalog number: 
12001-650), 50 ml Fetal Bovine Serum (Invitrogen, Catalog number: 16000-044), 
10 ml Pen-Strep (Fisher Scientific, Catalog number: SV30010), adjust pH to 7.3 
with HCl/NaOH, filter with Steritop filters (Millipore, Catalog number: 
SCGPT05RE) 
 
0.05% Trypsin-EDTA (1x), phenol red (Invitrogen, Catalog number: 25300-054) 
PBS (Invitrogen, Catalog number: 10010-023) 
70% Ethanol in water 
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D.2.   Equipments 
Clean 37°C water bath 
Personal protective equipment (sterile gloves, laboratory coat, safety goggle) 
Biosafety Cabinet Class II 
37°C and 5% CO2 Incubator 
Aspirator, centrifuge, pipette 
 
D.3.   Procedure 
1. Here HCT116-MKI67-1000 GFP cell line is used as an example, for H4IIE cells 
the general procedures are the same while the medium need to be changed to 
ALPHA-MEM. 
2. Warm PRMI 1640 medium and trypsin-EDTA in the 37°C water bath for about 
15 min, and turn on the centrifuge machine ahead if cooling function is included.  
Label the centrifuge tube and new culture flask as below: 
HCT116-MKI67-1000 
GFP 
                09/09/2011 
                         HAN 
 
3. For a T25 culture flask, remove old medium with aspirator  
(cap the glass tip with disposable 10 µl pipet tips for each use) 
4. Pipet 5 ml PBS (for T75 flask and petri dish, use 10 ml) gently into the T25 flask, 
gently shake for 30 s 
5. Remove PBS with aspirator, and add in 1 ml trypsin-EDTA (for T75 and petri 
dish use 2 ml).  Keep the culture flask in the incubator for about 5 min 
6. Observe the cell detaching under the microscope, after this process finishes wash 
the cell suspension with 4 ml of medium (for T25 and petri dish 8 ml is needed to 
reach 10 ml of final volume) and transfer the solution into 15 ml centrifuge tube 
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7. Centrifuge at 800-1000 rpm for 4:30 min to 5min (higher rpm and longer 
centrifuge would increase cell aggregation).  For centrifuges without cooling 
function, the centrifuge holders need to be kept in the 4°C refrigerator.  For 
centrifuges with cooling function, the centrifuge needs to be pre-cooled.  This is 
to reduce cell adhesion to sidewall and enhance cell pellet separation from basal 
medium 
8. Remove the supernatant with the aspirator.  Add 5 ml RPMI1640 medium to the 
new T25 culture flask and resuspend the cell pellets to 2 ml in fresh medium.  
Split the cell suspension at 1:6–1:8 ratio to the new culture flask 
9. Keep the cells in a 37°C and 5% CO2 incubator 
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APPENDIX E 
CELL STAINING PROTOCOL 
 
E.1.   Materials and Reagents 
[HCT116-MKI67-1000 GFP] (RPMI 1640) 
1 L: RPMI 1640 medium: RPMI 1640 (Invitrogen, Catalog number: 11875-085) 
with 10% Fetal Bovine Serum (Invitrogen, Catalog number: 16000-044), 20 mM 
HEPES (Invitrogen, Catalog number: 15630-080), 2-4 mM additional L-
Glutamine and 100 units/ml of Penicillin/Streptomycin (equivalent to 10ml 
Penicillin-Streptomycin-Glutamine (100X), liquid, Invitrogen, Catalog number: 
10378-016) 
(all given numbers are the final concentration) 
 
0.05% Trypsin-EDTA (1x), phenol red (Invitrogen, Catalog number: 25300-054) 
PBS (Invitrogen, Catalog number: 10010-023) 
70% Ethanol in water 
Centrifuge tubes (Corning®, Catalog number: 430052) 
T25 Cell culture flask (BD Falcon™, Catalog number: 353108) 
Vybrant® DyeCycle™ Violet stain *5 mM in water (Invitrogen, Catalog 
number: V35003) 
Microcentrifuge tubes (Fisher Scientific, Catalog number: 05-408-129) 
 
E.2.   Equipments 
Clean 37°C water bath 
Personal protective equipment (sterile gloves, laboratory coat, safety goggle) 
Biosafety Cabinet Class II 
37°C and 5% CO2 Incubator 
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Aspirator, centrifuge, pipette 
 
E.3.   Procedure 
1. For a T25 cell culture flask (> 90% confluency), follow the steps instructed in the 
cell culture protocol to prepare cell pellets from centrifuge 
2. Use the aspirator to remove the supernatant.  Resuspend the cell pellets to 1 ml in 
RPMI 1640 medium and gently pipet to allow mixing 
3. Perform cell counting as instructed in the separate protocol and prepare a 1 ml 
cell solution microcentrifuge tube at the density of 1×10
6
 cells/ml 
4. Add in DyeCycle™ Violet stain at 5 μM  
5. Concentrations need to be adjusted according to the fluorescence intensity 
measurement 
6. Wrap the mixed cell stain solution tubes with aluminum and keep it in the 37°C 
and 5% CO2 incubator for 30 min.  Protect from light 
7. Resuspend cells into desired density and perform cell culture and analysis.  To 
achieve higher density another step of centrifuge can be performed 
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Figure E.1.  HCT116-MKI67-1000 GFP cells in the microfluidic device.  (A) 
Brightfield image of the HCT116-MKI67-1000 GFP cells seeded in the microfluidic 
device.  (B) Blue fluorescence image of cells in (A) showing nuclei stained with 
DyeCycle™ Violet stain at 5 µM.  (C) Green fluorescence image of the cells in (A) 
showing GFP reporter expression.  (D) Merged image of the blue and green fluorescence 
channels. 
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APPENDIX F 
OPERATION CONTROL AND DATA ACQUISITION 
 
Device operation and data acquisition were automatically controlled by user 
made LabVIEW
TM
 programs. 
F.1. MICROFLUIDIC NETWORK-BASED LIVE CELL COMBINATION DRUG 
SCREENING PLATFORM 
 
Figure F.1.  Front panel of the LabVIEW
TM
 program for microfluidic network-
based combination drug screening system (2Xmas-sequential__20100410.vi). 
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Figure F.2.  Block diagram of the LabVIEW
TM
 program for microfluidic network-
based combination drug screening system (2Xmas-sequential__20100410.vi). 
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F.2. MICROFLUIDIC GEOMETRIC METERING-BASED LIVE CELL TOXIN 
SCREENING PLATFORM 
 
Figure F.3.  Front panel of the LabVIEW
TM
 program for microfluidic geometric 
metering-based live cell toxin screening system (Geometric toxin 
screeing_toxin__20110715.vi). 
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Figure F.4.  Block diagram of the LabVIEW
TM
 program for microfluidic geometric 
metering-based live cell toxin screening system (Geometric toxin 
screeing_toxin__20110715.vi). 
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